phrykt

IDEAYA Biosciences, Inc. (IDYA): who owns it and who trades it

As of Nov 16, 2026, IDYA insiders reported 3 open-market sales worth $1.4M and 1 purchase worth $1.6M in the last 12 months, with 72% of the sale value made under pre-set 10b5-1 plans. The largest seller was Yujiro S Hata (CEO), with $985K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling IDEAYA Biosciences

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds and insiders were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IDYA

283 funds and institutions reported IDYA shares worth $3.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 16.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)16.1%
BlackRock, Inc.10.1%
Jupiter Topco LLC9.8%
Capital Research Global Investors6.1%
Baker Bros. Advisors LP5.7%
State Street Corp5.2%
Vanguard Capital Management LLC4.7%
California State Teachers Retirement System4.0%
Logos Global Management LP3.4%
Adage Capital Partners Gp, L.l.c.3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)14.11M16.06%$526M+7%
BlackRock, Inc.8.89M10.12%$331M+5%
Jupiter Topco LLC8.58M9.77%$320M–
Capital Research Global Investors5.34M6.08%$199M+4%
Baker Bros. Advisors LP5.01M5.70%$187M+27%
State Street Corp4.55M5.18%$170M+20%
Vanguard Capital Management LLC4.13M4.70%$154M+11%
California State Teachers Retirement System3.50M3.98%$93.9M+3522%
Logos Global Management LP3.00M3.41%$112M-13%
Adage Capital Partners Gp, L.l.c.2.72M3.09%$101M-4%
Deerfield Management Company, L.P.2.71M3.09%$101M+77%
Geode Capital Management, LLC2.43M2.76%$90.4M-3%
T. Rowe Price Associates2.21M2.51%$82.3M+68%
Morgan Stanley1.93M2.20%$72M+4%
Dimensional Fund Advisors LP1.66M1.89%$61.9M+25%
Alliancebernstein L.P.1.63M1.85%$54.2M+1515%
Fiera Capital Corp1.45M1.65%$53.9M-43%
Federated Hermes, Inc.1.43M1.63%$53.4M-52%
GSK plc1.33M1.52%$49.7MNo change
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.27M1.45%$47.3M+15%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IDYA insiders reported $1.6M of open-market purchases and $1.4M of sales. 72% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.6M
1 trades, 1 people
Sales, 12 months
$1.4M
3 trades, 2 people
Sales under a 10b5-1 plan
72%
Share of sale value
Latest trade
Oct 6, 2026
Filed Oct 8, 2026

Purchases and sales by month

$1.6M$1.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 6, 2026Yujiro S HataCEOSale plan25,538$37.39$955KForm 4
Oct 6, 2026Yujiro S HataCEOSale plan800$38.26$30.6KForm 4
Jul 7, 2026Briseno Andres RuizChief Accounting OfficerSale9,550$40.01$382KForm 4
Mar 2, 2026Jeffrey SteinDirectorPurchase50,000$32.96$1.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jeffrey SteinDirector$1.6M–Mar 2, 2026
Yujiro S HataPresident and CEO, Director–$985KOct 6, 2026
Briseno Andres RuizChief Accounting Officer–$382KJul 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IDYA short interest

Moderate short interest. 8.5% of IDYA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 30%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.24M IDYA shares were sold short, 8.5% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 928,512 shares, buying them all back would take about 8.9 trading days (days to cover).

Shares short, % of all shares

8.54%May 15Oct 3014.0%

Days to cover

8.9May 15Oct 3018.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.24M8.54%-9%928,5128.9
Oct 15, 20269.08M9.41%-1%754,63412.0
Sep 30, 20269.18M9.52%-8%1.09M8.4
Sep 15, 20269.93M10.29%-2%575,24817.3
Aug 31, 202610.10M10.47%-3%827,36012.2
Aug 14, 202610.40M10.78%+3%629,93916.5
Jul 31, 202610.11M10.48%+6%766,53113.2
Jul 15, 20269.57M10.90%-7%1.11M8.6
Jun 30, 202610.33M11.76%-3%1.70M6.1
Jun 15, 202610.63M12.10%-6%1.41M7.5
May 29, 202611.34M12.90%-3%693,87416.3
May 15, 202611.70M13.32%No change838,48214.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

IDEAYA Biosciences company events

IDEAYA Biosciences filed 15 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jun 23, 2026AnnouncementThe Company’s Board of Directors elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as the Board’s Lead Independent Director. Filing
  4. Jun 10, 2026AnnouncementIDEAYA Biosciences, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and… Filing
  5. Jun 3, 2026AnnouncementIDEAYA Biosciences, Inc. announced it has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class PRMT5 inhibitor, in combination with Roche’s RG6505, a pan-RAS inhibitor, in patients with… Filing
  6. Jun 1, 2026AnnouncementIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO On June 1, 2026, the Company and Les Laboratoires Servier… Filing
  7. May 5, 2026AnnouncementIDEAYA Biosciences, Inc. filed with the Securities and Exchange Commission an automatic shelf registration statement on Form S-3ASR (Registration No. 333-295560) to replace its existing automatic shelf registration statement on Form S-3 (Registration No. 333-272936) filed with the SEC on June 26… Filing
  8. May 5, 2026ResultsReleased financial results. Filing
  9. Apr 13, 2026AnnouncementMade another announcement. Filing
  10. Apr 9, 2026AnnouncementIDEAYA Biosciences, Inc. entered into a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, the Company’s investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s Imfinzi ® (durvalumab), a… Filing
  11. Feb 17, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026AnnouncementIDEAYA Biosciences, Inc. provided a business update including an overview of key corporate objectives for 2026. Filing
  13. Jan 12, 2026AnnouncementShared information with investors. Filing
  14. Dec 12, 2025AgreementEnded an important agreement. Filing
  15. Dec 5, 2025AnnouncementGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) communicated to IDEAYA Biosciences, Inc. its election to terminate the Collaboration, Option and License Agreement, dated June 15, 2020 (as amended, the “Agreement”). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

IDEAYA Biosciences financials

Famous investors that hold IDYA

2 of the 50 well-known investors we track reported holding IDYA in their latest 13F filing. The largest position is Ken Fisher's, worth $31.1M.

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 2026810,671$31.1M0.0%-5%
Paul Tudor Jones · Tudor Investment CorpQ3 202613,156$505K0.0%-71%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about IDEAYA Biosciences, Inc. (IDYA) stock

Who owns the most IDYA stock?

The largest reported owner of IDEAYA Biosciences, Inc. (IDYA) is FMR LLC (Fidelity), with 16.1% of the company. In total, 283 funds and institutions reported holding IDYA at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are IDYA insiders buying or selling?

In the last 12 months, IDYA insiders reported 1 open-market purchase worth $1.6M and 3 sales worth $1.4M. The latest trade was on Oct 6, 2026. See every trade.

What is the short interest in IDYA?

As of Oct 30, 2026, 8.24M IDYA shares were sold short, 8.5% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 928,512 shares, buying them all back would take about 8.9 trading days (days to cover). See the history.

Which famous investors hold IDYA?

2 of the 50 well-known investors we track reported IDYA in their latest 13F filing, including Ken Fisher, Paul Tudor Jones. The largest position is worth $31.1M. See all holders.

Executive pay

IDEAYA Biosciences's chief executive was paid a total of $9.5M for the year ended Dec 31, 2025, down 44% from $16.9M the year before. In the last 12 months, IDEAYA Biosciences's executives and directors bought $1.6M of stock on the open market and sold $1.4M.

Chief executive, total pay$9.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$15.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.